Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing | Zendy

Thuy Nguyen | Zendy; Djeneba Fofana | Zendy; Minh Patrick Lê | Zendy; Charlotte Charpentier | Zendy; Gilles Peytavin | Zendy; Marc Wirden | Zendy; Sidonie Lambert-Niclot | Zendy; Nathalie Désiré | Zendy; Maxime Grudé | Zendy; Laurence MorandJoubert | Zendy; Philippe Flandre | Zendy; Christine Katlama | Zendy; Diane Descamps | Zendy; Vincent Cálvez | Zendy; Ève Todesco | Zendy; AnneGeneviève Marcelin | Zendy

Open Access

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

Author(s) -

Thuy Nguyen,

Djeneba Fofana,

Minh Patrick Lê,

Charlotte Charpentier,

Gilles Peytavin,

Marc Wirden,

Sidonie Lambert-Niclot,

Nathalie Désiré,

Maxime Grudé,

Laurence MorandJoubert,

Philippe Flandre,

Christine Katlama,

Diane Descamps,

Vincent Cálvez,

Ève Todesco,

AnneGeneviève Marcelin

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky198

Subject(s) - dolutegravir , elvitegravir , raltegravir , sanger sequencing , regimen , medicine , integrase , deep sequencing , virology , human immunodeficiency virus (hiv) , mutation , genetics , viral load , biology , gene , antiretroviral therapy , genome

Integrase strand transfer inhibitors (INSTIs) are recommended by international guidelines as first-line therapy in antiretroviral-naive and -experienced HIV-1-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research